For example, MRX34 (a mimetic of miR-34) was used in a clinical trial to treat melanoma, primary liver cancer, and hematological malignancies, but was forced to discontinue due to severe immune reactions in patients (NCT01829971). Here, IL1RAPL1 is linked to melanoma.